$1.52 Billion is the total value of NEA Management Company, LLC's 35 reported holdings in Q3 2015. The portfolio turnover from Q2 2015 to Q3 2015 was 80.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| PRTK | Sell | PARATEK PHARMACEUTICALS INC | $2,375,000 | -47.0% | 125,004 | -28.1% | 0.16% | -33.3% |
| ABIO | Exit | ARCA BIOPHARMA INC | $0 | – | -10,221,465 | -100.0% | -0.61% | – |
| TRGT | Exit | TARGACEPT INC | $0 | – | -4,566,666 | -100.0% | -0.66% | – |
| SNSS | Exit | SUNESIS PHARMACEUTICALS INC | $0 | – | -4,659,333 | -100.0% | -0.73% | – |
| VTAE | Exit | VITAE PHARMACEUTICALS INC | $0 | – | -2,613,199 | -100.0% | -1.96% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-11-10
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| GLYCOMIMETICS INC | 39 | Q3 2023 | 7.6% |
| AURINIA PHARMACEUTICALS INC | 37 | Q3 2023 | 5.0% |
| CHAMPIONS ONCOLOGY INC | 33 | Q3 2023 | 1.2% |
| LEXICON PHARMACEUTICALS INC | 32 | Q3 2023 | 2.0% |
| ADAPTIMMUNE THERAPEUTICS PLC | 31 | Q3 2023 | 9.3% |
| TREVENA INC | 31 | Q3 2021 | 3.3% |
| AKARI THERAPEUTICS PLC | 31 | Q2 2023 | 0.3% |
| ARDELYX INC | 29 | Q3 2021 | 11.9% |
| RIGEL PHARMACEUTICALS INC | 29 | Q2 2020 | 0.6% |
| EPIZYME INC | 28 | Q1 2020 | 9.6% |
View NEA Management Company, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-10 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
View NEA Management Company, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.